What Quadracel Treats: Main Uses and Benefits

Protection Against Severe Neuromuscular and Respiratory Disease

Quadracel is a vaccine indicated for active immunization against four specific, severe infectious diseases: Diphtheria, Tetanus, Pertussis (Whooping Cough), and Poliomyelitis (Polio). Its therapeutic use is applied across domains where additional symptomatic support is needed, particularly for symptom clusters that involve life-threatening respiratory distress (e.g., airway obstruction, violent coughing) and profound neuromuscular dysfunction (e.g., paralysis, painful muscle spasms), and may assist with maintaining protection against these catastrophic outcomes. This preventative use is considered relevant for easing the impact of severe illness.

Maintaining Long-Term Immunity through Routine Boosting

The vaccine is generally applied in the context of the childhood immunization schedule as a booster dose for children aged 4 through 6 years. This use is relevant for maintaining the protective immunity gained from earlier doses, helps maintain a sense of stability against the severe, long-term complications of these diseases, and is relevant in contexts marked by temporary physiological imbalance due to waning immunity.

Quadracel is commonly used as a combined formulation and offers the therapeutic benefit of convenience. It assists with simplifying the process of receiving essential protection against four pathogens simultaneously, which is highly relevant in the real-world context of routine pediatric preventative care by assisting with maintaining functional stability in the vaccination schedule.

Quick Fact: Prophylaxis of Severe Symptoms

Quadracel is a vaccine with a strictly defined eligibility profile based on age and patient history, as documented by regulatory authorities.

Approved Population

Use is strictly limited to children 4 through 6 years of age. It is indicated for those who require the fifth dose in the Diphtheria, Tetanus, and Acellular Pertussis (DTaP) series and the fourth or fifth dose in the Inactivated Poliovirus (IPV) series. The vaccine is not approved or recommended for children under 4 years of age or 7 years and older, and its use in adult or geriatric populations is not established.

Absolute Contraindications

Quadracel must not be administered to individuals who have experienced a severe allergic reaction (anaphylaxis) to any component of the vaccine or following a previous dose of any component-containing vaccine. It is also contraindicated in any individual who developed encephalopathy within 7 days of a previous pertussis-containing vaccine where no other cause was found, or who has an uncontrolled or progressive neurologic disorder.

Eligibility-Related Restrictions

Regulatory labeling requires careful consideration before administration if a person has a history of Guillain-Barré syndrome (GBS) within six weeks of a prior tetanus toxoid-containing vaccine. Similarly, specific severe reactions following a previous pertussis-containing vaccine (such as high fever ge 40.5 C or hypotonic-hyporesponsive episode) necessitate a risk-benefit assessment. Altered immunocompetence may result in a suboptimal immune response.

Quadracel’s official interaction profile, as documented by regulatory authorities, centers on minimizing interference with the immune response and adhering to mandatory administration rules.

The primary documented interaction is a pharmacodynamic one involving Immunosuppressive Therapy. Co-administration with medicinal products such as corticosteroids, alkylating agents, antimetabolites, or cytotoxic drugs may compromise the body's ability to mount the expected immune response. If the vaccine is administered while a patient is receiving immunosuppressive treatment, a limited or sub-optimal antibody response may be obtained, reducing the vaccine’s effectiveness. This interaction risk is an explicit consideration for immunocompromised persons noted in the official labeling.

Procedural constraints govern the co-administration of the vaccine with other medicinal products. Quadracel is subject to a strict restriction that it must not be combined or mixed with any other vaccine or medicinal product in the same syringe or vial. When administered simultaneously with other childhood vaccines (e.g., Measles, Mumps, and Rubella; Varicella), the official requirement mandates the use of separate syringes and separate injection sites or limbs. The only specified exception to this mixing rule is the use of the vaccine to reconstitute the Act-HIB (Haemophilus b Conjugate Vaccine) for a single injection.

Quadracel's mechanism involves the presentation of purified, inactivated, or detoxified microbial components to the host immune system, a process termed active immunization. The biological targets include: diphtheria toxoid, tetanus toxoid, five acellular pertussis antigens (detoxified pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3), and inactivated polioviruses (types 1, 2, and 3). The antigens are adsorbed onto aluminum phosphate, which serves as an adjuvant to facilitate sustained antigen presentation at the injection site. This interaction triggers the activation of antigen-presenting cells, initiating the molecular and intracellular pathway of T- and B-lymphocyte activation. Downstream cascades include the clonal expansion of B-cells and their differentiation into plasma cells, which synthesize and secrete specific antibodies. The system-level physiological consequence is the induction of circulating antitoxins targeting diphtheria and tetanus neurotoxins, type-specific neutralizing antibodies against polioviruses, and antibodies against the acellular pertussis components. These specific antibodies circulate systemically and constitute a modified adaptive immune response.

Administration Instructions for Quadracel

The use of Quadracel follows standardized procedures which outline the required dose, route, and age-specific timing.

Dosage and Schedule

Quadracel is administered as a single 0.5 mL dose.

• Age-Specific Use: The vaccine is for use in children 4 through 6 years of age.
• Immunization Series Role: It is used as a fifth dose in the Diphtheria, Tetanus, and Acellular Pertussis (DTaP) vaccination series, and as a fourth or fifth dose in the Inactivated Poliovirus (IPV) series, provided the child has a history of specific prior DTaP doses.

Preparation and Administration Route

Quadracel is given only by intramuscular injection.

These instructions define the standardized protocol for use, restricting the administration to a specific age range and injection method.

Research evidence / Overview of studies for Quadracel

Evidence for Routine Booster Immunization

The research used to support regulatory review was based on Pivotal Phase III Randomized Controlled Trials (RCTs). These studies were designed to evaluate the combined vaccine against the individual vaccine components (DTaP and IPV) administered separately.

The core of the evidence explored Immunogenicity, which is the measurement of the body's response to the vaccine components. Studies monitored the levels of specific antibodies (serological endpoints) created in the observed populations. Findings describe patterns observed in the studies that show the measured immune responses were similar to those observed when the components were given separately. Research examined the combined administration of the four components.

Study Focus on Immunological Endpoints

This part details the outcomes that were measured in the research studies. The trials examined the proportion of individuals who reached target antibody concentrations (seroprotection levels) for diphtheria, tetanus, and the three types of poliovirus. Researchers also monitored the rise in antibodies against the pertussis components. These measurements of immune response, rather than direct counts of disease prevention, were the focus of the evidence submitted to regulators.

Long-Term Protection and Follow-Up Data

The pivotal clinical trials used a short-term follow-up duration. Key serological endpoints were evaluated approximately 28 days after vaccination. This initial research provides insight into short-term changes immediately following the booster dose.

Long-term duration of the immune response is not well characterized by the initial clinical trials, as their design focused on short follow-up periods. Research exploring how antibody levels may change over extended periods is supported by ongoing surveillance or modeling studies.

Evidence in Specific Pediatric Populations

The main research was conducted in a narrowly defined population of children aged 4 through 6 years who were receiving their final DTaP and IPV booster doses. The results apply only to the populations studied.

Key Research Gaps and Remaining Uncertainties

The core limitation of the research is that direct protection from disease was not measured as a primary outcome in the pivotal trials. The primary finding is an indirect one, where the evidence is based on inferred protection through the level of antibody production, known as immunological correlates.

Furthermore, follow-up durations were limited to the short term, meaning there is limited information for long-term outcomes and the durability of the immune response years after the booster. Research provides context but not individual predictions, and the studies reflect the specific conditions under which they were conducted.

Common questions about Quadracel (FAQ)

Q: What should be known about the Diphtheria and Tetanus components in Quadracel?

The Diphtheria and Tetanus components are modified bacterial toxins, which are officially called toxoids. These toxoids have been chemically inactivated so they cannot cause the actual diseases.

According to the official product information, their purpose is to stimulate the immune system to create protective antibodies.

Q: What does the 'acellular' part of the pertussis component in Quadracel mean?

The term 'acellular' refers to the Pertussis component in the vaccine formulation. It means the vaccine uses purified, specific parts (antigens) of the Bordetella pertussis bacterium, rather than the entire cell.

The acellular components are associated with potential better local tolerance compared to older whole-cell formulations.

Q: How long after administration should the protection from Quadracel be considered fully effective?

Official clinical studies evaluate the effectiveness of the vaccine by measuring the immune response it creates.

Clinical studies typically measure the resulting antibody levels (immunological endpoints) approximately 28 days following the administration of the vaccine.

Q: Is it true that the effectiveness of the Pertussis component wears off over time?

Initial clinical trials for the Quadracel booster focused on short-term follow-up periods. Research from public health organizations suggests that the protection provided by the acellular pertussis component may gradually decrease over extended periods.

This is consistent with the standard schedule of booster doses recommended by public health authorities.

Q: What is the official description of a Hypotonic-Hyporesponsive Episode (HHE) potentially associated with Quadracel?

A Hypotonic-Hyporesponsive Episode (HHE) is reported as a rare adverse event during post-marketing surveillance. Official safety documents describe HHE as an event that may involve a child experiencing collapse or a temporary shock-like state.

It is classified in the safety profile as a reaction whose frequency is not known.

Q: Is severe swelling of the entire limb at the injection site a known reaction to Quadracel, and why does it happen?

Extensive swelling or redness that involves the entire limb at the injection site is a documented local reaction.

Official safety data notes that local reactions may be observed more frequently after later booster doses in the DTaP series.

Q: What signs of a severe allergic reaction (anaphylaxis) to Quadracel are listed in the product documents?

A history of a severe allergic reaction (anaphylaxis) to any vaccine component is listed as an eligibility factor that restricts the use of future doses.

Signs of anaphylaxis may include hives, difficulty breathing, and swelling of the face, lips, tongue, or throat.

Q: Where can I find the official, regulatory-approved patient information (CMI) for Quadracel?

Official regulatory-approved patient information is available in several formats. This includes the Patient Medication Information (PMI) published by the manufacturer and the official FDA Package Insert.

Public health organizations may also provide educational materials based on the official product labeling.

Q: Are there official statements regarding the risk of high fever or inconsolable crying after Quadracel?

Fever is listed as a very common side effect in the official safety profile. The possibility of persistent, inconsolable crying lasting three hours or more within 48 hours after a previous dose is also noted in the Warnings and Precautions section.

A history of this type of reaction is an eligibility factor that health professionals must consider before any subsequent dose.

Q: Is there a maximum number of doses of DTaP-IPV combined vaccines a child can receive?

The approved schedule for the Diphtheria, Tetanus, and Acellular Pertussis (DTaP) series consists of five doses as part of the routine immunization schedule.

Quadracel is specifically approved for use as the fifth dose in the DTaP series.

Q: Can Quadracel be given simultaneously with the seasonal flu vaccine?

According to official instructions, Quadracel may be administered at the same time as other age-appropriate vaccines, including the seasonal flu vaccine.

However, official administration instructions specify that separate syringes and separate injection sites should be used for each vaccine administered at the same time.

Q: Are the components of Quadracel the same as those in Daptacel and IPOL vaccines?

Regulatory documents confirm the specific active components of Quadracel. While professional guidance generally suggests using the same manufacturer’s DTaP vaccines for each dose when feasible, official statements clarify that vaccination may proceed even if the previous DTaP brand is unavailable or unknown.

Q: How does Quadracel's formulation compare to other DTaP-IPV combination vaccines, such as Kinrix?

Official labeling states the components of Quadracel. Regulatory agencies do not typically conduct or publish comparative assessments of superiority between different licensed DTaP-IPV brands.

Professional guidance suggests that using the same DTaP brand when feasible is generally preferred.

Q: Does Quadracel contain any preservatives like thimerosal or mercury?

According to the official product monograph, Quadracel does not contain thimerosal or mercury as a preservative.

It does contain Aluminum phosphate, which serves as an adjuvant (a substance used to enhance the immune response).

Q: Are there any trace antibiotics or components in Quadracel that could cause allergic reactions?

Official product information states that residual trace amounts of materials used during the manufacturing process may be present.

These trace amounts can include formaldehyde, glutaraldehyde, bovine serum albumin, neomycin, and polymyxin B sulphate.

Q: What should be considered if a child has a moderate or severe fever on the day the Quadracel is scheduled?

The official guidance advises against administering the vaccine to a child who has a high fever or is experiencing a serious acute illness.

Official guidance indicates that vaccination may be postponed until the child has recovered and the acute illness has resolved.

Q: Is it safe to give common over-the-counter fever reducers around the time of the Quadracel dose?

Official product information notes that, for children with a higher risk of seizures, the administration of a fever-reducing medication may be considered.

This information pertains to mitigating expected temporary reactions after the dose.

Q: What is the recommended minimum time interval between the fourth dose of DTaP and Quadracel?

According to official dosing and administration instructions, the minimum time interval required between the fourth dose of DTaP and the fifth dose (Quadracel) should be at least six months.

This minimum interval is specified to allow for an adequate booster immune response.

Q: If a child received a different brand for their previous DTaP doses, can they still get Quadracel?

While professional guidance suggests using the same DTaP brand when feasible, official statements clarify that vaccination may proceed even if the previous DTaP brand is unavailable or unknown.

Any of the licensed DTaP vaccines may be used to complete the series.

Q: What is the process for health professionals to report a potential adverse reaction to Quadracel?

In the United States, official regulatory bodies manage the Vaccine Adverse Event Reporting System (VAERS).

Suspected adverse reactions should be reported to this system, which is jointly administered by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA).

Q: Why is the polio component (IPV) included in the DTaP booster given at this age?

The polio component is included in the combination vaccine to ensure the child receives the necessary booster dose of Inactivated Poliovirus Vaccine (IPV).

Public health rationale states this component is included to help complete the immunization series and support long-term immunity against poliomyelitis.

Q: How does the concentration of the diphtheria component in Quadracel compare to other DTaP vaccines?

Quadracel is designated as a DTaP vaccine, which is indicated by the uppercase 'D' for the diphtheria component.

This formulation contains a full-strength dose of diphtheria toxoid, which is the standard amount for the pediatric immunization series.

The official regulatory documentation for Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) specifies precise conditions for its storage and handling.

Storage Requirements

Quadracel must be stored in a refrigerator at a temperature range of 2 C to 8 C (35 F to 46 F).

• Do not freeze the vaccine; freezing destroys the product, and it must be discarded if exposed to freezing temperatures.
• The product must be stored in the original container to protect it from light and be kept out of the sight and reach of children.
• The vaccine must not be administered if particulate matter or discoloration is observed upon visual inspection.

Disposal Instructions

Any unused or expired Quadracel must be discarded. Disposal of the vaccine and related materials must be carried out in compliance with all local and national regulations for pharmaceutical waste, and it should not be thrown into household trash or wastewater.